Richard Vickers

1.6k citations

35 papers · 1.0k indexed · h-index 23

Co-authors: Stephen G. Davies Mark H. Wilcox Andrew W. Mulvaney Edith Sim Frédérique Pompeo Kevin W. Garey Jane Freeman Andrew D. Smith
Topics: Clostridium difficile and Clostridium perfringens research (18 papers)Microscopic Colitis (11 papers)Gut microbiota and health (6 papers)
Cited by: Infectious Diseases Molecular Medicine Organic Chemistry
Journals: PLoS ONE Antimicrobial Agents and Chemotherapy Journal of Antimicrobial Chemotherapy
Partner nations: United Kingdom United States Australia

In The Last Decade

Richard Vickers

35 papers receiving 1.0k citations

Peers

Countries citing papers authored by Richard Vickers

Since Specialization

Citations

This map shows the geographic impact of Richard Vickers's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Richard Vickers with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Richard Vickers more than expected).

Fields of papers citing papers by Richard Vickers

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Richard Vickers. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Richard Vickers. The network helps show where Richard Vickers may publish in the future.

Co-authorship network of co-authors of Richard Vickers

This figure shows the co-authorship network connecting the top 25 collaborators of Richard Vickers. A scholar is included among the top collaborators of Richard Vickers based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Richard Vickers. Richard Vickers is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Ridinilazole, a narrow spectrum antibiotic for treatment of Clostridioides difficile infection, enhances preservation of microbiota-dependent bile acids 2020 ·American Journal of Physiology-Gastrointestinal and Liver Physiology ·(unknown),(unknown),Anne Kane,Nicholas Alden,Ming Lei,David R. Snydman,Richard Vickers,Kyongbum Lee,Cheleste M. Thorpe	33
2	Combating Resistance While Maintaining Innovation: The Future of Antimicrobial Stewardship 2019 ·Future Microbiology ·Richard Vickers,Matteo Bassetti,Cornelius J. Clancy,Kevin W. Garey,David E. Greenberg,(unknown),David Roblin,Glenn Tillotson,Mark H. Wilcox	19
3	Enhanced preservation of the human intestinal microbiota by ridinilazole, a novel Clostridium difficile-targeting antibacterial, compared to vancomycin 2018 ·PLoS ONE ·Cheleste M. Thorpe,Anne Kane,Justin Chang,Albert Tai,Richard Vickers,David R. Snydman	43
4	1344. Ridinilazole (RDZ) for Clostridium difficile Infection (CDI): Impact of Diagnostic Method on Outcomes From a Phase 2 Clinical Trial 2018 ·Open Forum Infectious Diseases ·Richard Vickers,(unknown),Mark H. Wilcox	2
5	A novel method for imaging the pharmacological effects of antibiotic treatment on Clostridium difficile 2016 ·Anaerobe ·Bradley T. Endres,Eugénie Bassères,(unknown),(unknown),Mohammad Jahangir Alam,Richard Vickers,Ioannis A. Kakadiaris,Kevin W. Garey	4
6	Impact on toxin production and cell morphology inClostridium difficileby ridinilazole (SMT19969), a novel treatment forC. difficileinfection 2016 ·Journal of Antimicrobial Chemotherapy ·Eugénie Bassères,Bradley T. Endres,Mohammed Khaleduzzaman,(unknown),Mohammad Jahangir Alam,Richard Vickers,Kevin W. Garey	44
7	A randomised phase 1 study to investigate safety, pharmacokinetics and impact on gut microbiota following single and multiple oral doses in healthy male subjects of SMT19969, a novel agent for Clostridium difficile infections 2015 ·BMC Infectious Diseases ·Richard Vickers,(unknown),Emma L. Best,Roger Echols,Glenn Tillotson,Mark H. Wilcox	34
8	Synthesis and evaluation of the 2,4-diaminoquinazoline series as anti-tubercular agents 2014 ·Bioorganic & Medicinal Chemistry ·Joshua Odingo,Theresa O’Malley,Edward A. Kesicki,Torey Alling,Mai A. Bailey,Julie V. Early,Juliane Ollinger,(unknown),(unknown),Ravindra Singh,Philip A. Hipskind,Jeffrey W. Cramer,Thomas R. Ioerger,James C. Sacchettini,Richard Vickers,Tanya Parish	26
9	SMT19969 as a treatment for Clostridium difficile infection: an assessment of antimicrobial activity using conventional susceptibility testing and an in vitro gut model 2014 ·Journal of Antimicrobial Chemotherapy ·Simon D. Baines,G. S. Crowther,Jane Freeman,S. L. Todhunter,Richard Vickers,Mark H. Wilcox	35
10	Bioorganic & Medicinal Chemistry 22 (2014) 6965–6979 2014 ·(unknown),Theresa O’Malley,Edward A. Kesicki,Torey Alling,Mai A. Bailey,Julie V. Early,Juliane Ollinger,(unknown),(unknown),Ravindra Singh,Philip A. Hipskind,Jeffrey W. Cramer,Thomas R. Ioerger,James C. Sacchettini,Richard Vickers,(unknown)	24
11	Automated Large-Scale Culture and Medium-Throughput Chemical Screen for Modulators of Proliferation and Viability of Human Induced Pluripotent Stem Cell–Derived Neuroepithelial-like Stem Cells 2012 ·SLAS DISCOVERY ·(unknown),Thorsten Gorba,(unknown),(unknown),(unknown),Alison Stacey,(unknown),Anna Falk,Austin Smith,Philipp Koch,Oliver Brüstle,Richard Vickers,Jon Tinsley,David J. Flanders,Paul Bello,Stewart Craig	28
12	Discovery and SAR of 2-arylbenzotriazoles and 2-arylindazoles as potential treatments for Duchenne muscular dystrophy 2011 ·Bioorganic & Medicinal Chemistry Letters ·(unknown),(unknown),Peter D. Johnson,Adam Lambert,(unknown),(unknown),(unknown),(unknown),(unknown),R.J. Pye,Richard Storer,Jonathon M. Tinsley,Richard Vickers,(unknown),Fraser J. Wilkes,Francis X. Wilson,Stephen P. Wren,Graham M. Wynne	16
13	Identification of arylamine N-acetyltransferase inhibitors as an approach towards novel anti-tuberculars 2010 ·Protein & Cell ·Isaac M. Westwood,Sanjib Bhakta,Angela J. Russell,Elizabeth Fullam,Matthew C. Anderton,Akane Kawamura,Andrew W. Mulvaney,Richard Vickers,Veemal Bhowruth,Gurdyal S. Besra,Ajit Lalvani,Stephen G. Davies,Edith Sim	40
14	An oxidatively-activated safety catch linker for solid phase synthesis 2008 ·Organic & Biomolecular Chemistry ·Stephen G. Davies,(unknown),Andrew W. Mulvaney,Angela J. Russell,(unknown),Andrew D. Smith,Richard Vickers	7
15	Diastereoselective synthesis of quaternary α-amino acids from diketopiperazine templates 2007 ·Organic & Biomolecular Chemistry ·Stephen G. Davies,A. Christopher Garner,(unknown),Paul M. Roberts,Andrew D. Smith,(unknown),James E. Thomson,Juan A. Tamayo,Richard Vickers	24
16	Asymmetric synthesis and applications of β-amino Weinreb amides: asymmetric synthesis of (S)-coniine 2004 ·Organic & Biomolecular Chemistry ·Anthony J. Burke,Stephen G. Davies,A. Christopher Garner,Tom D. McCarthy,Paul M. Roberts,Andrew D. Smith,Humberto Rodríguez‐Solla,Richard Vickers	59
17	An approach to identifying novel substrates of bacterial arylamine N-acetyltransferases 2003 ·Bioorganic & Medicinal Chemistry ·(unknown),Stephen G. Davies,Andrew W. Mulvaney,Frédérique Pompeo,Edith Sim,Richard Vickers	73
18	Synthesis and in vitro evaluation of novel small molecule inhibitors of bacterial arylamine N-acetyltransferases (NATs) 2003 ·Bioorganic & Medicinal Chemistry Letters ·(unknown),Stephen G. Davies,Andrew W. Mulvaney,Minoru Okada,Frédérique Pompeo,Edith Sim,Richard Vickers,Isaac M. Westwood	55
19	Asymmetric synthesis of substituted 1-aminocyclopropane-1-carboxylic acids via diketopiperazine methodology 2003 ·Organic & Biomolecular Chemistry ·Elena Buñuel,Steven D. Bull,Stephen G. Davies,A. Christopher Garner,E.D. Savory,Andrew D. Smith,Richard Vickers,D.J. Watkin	22
20	Chirally templated boronic acid Mannich reaction in the synthesis of optically active α-amino acids 2000 ·Journal of the Chemical Society Perkin Transactions 1 ·Gordon S. Currie,Michael G. B. Drew,Laurence M. Harwood,David Hughes,Richard Luke,Richard Vickers	31

About Richard Vickers

Richard Vickers is a scholar working on Infectious Diseases, Applied Microbiology and Biotechnology and Developmental Neuroscience, having authored 35 papers that have together received 1.0k indexed citations. Recurring topics across this work include Clostridium difficile and Clostridium perfringens research (18 papers), Microscopic Colitis (11 papers) and Gut microbiota and health (6 papers). The work is most often cited by research in Infectious Diseases (399 citations), Molecular Medicine (55 citations) and Organic Chemistry (257 citations). Richard Vickers has collaborated with scholars based in United Kingdom, United States and Australia. Frequent co-authors include Stephen G. Davies, Mark H. Wilcox, Andrew W. Mulvaney, Edith Sim, Frédérique Pompeo, Kevin W. Garey, Jane Freeman, Andrew D. Smith, Glenn Tillotson and A. Christopher Garner. Their work appears in journals such as PLoS ONE, Antimicrobial Agents and Chemotherapy and Journal of Antimicrobial Chemotherapy.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact